Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12382071 | 0.83 | SRC (0.46) | PDE3BPDE3ASRCTNNI3K | |
| SCHEMBL1531608 | 0.78 | AKT1 (0.37) | CRBNAKT1AKT2AKT3TNNI3K | |
| SCHEMBL18297361 | 0.78 | KDR (0.42) | CRBNAKT1AKT2AKT3TNNI3K | |
| SCHEMBL12775785 | 0.77 | AKT1 (0.35) | PDE3BPDE3ACRBNAKT1AKT2 | |
| SCHEMBL12775969 | 0.75 | AKT1 (0.36) | CRBNAKT1AKT2AKT3DDB1 | |
| SCHEMBL21823060 | 0.75 | AKT1 (0.32) | CRBNAKT1AKT2AKT3TNNI3K | |
| SCHEMBL12775796 | 0.75 | AKT1 (0.34) | PDE3BPDE3ACRBNAKT1AKT2 | |
| SCHEMBL10267990 | 0.74 | PDE3B (0.40) | PDE3BPDE3ACRBNDDB1 | |
| SCHEMBL14494423 | 0.73 | PDE3B (0.39) | PDE3BPDE3ACRBN | |
| SCHEMBL24035072 | 0.73 | AKT1 (0.51) | AKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044077-B1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LTD (GB) | 2016-10-05 | — | — | EP | disclosed |
| WO-2008128942-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| US-7307082-B2 | Heterocyclic derivatives as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-12-11 | — | — | US | disclosed |
| US-20040224964-A1 | Heterocyclic derivatives as CRF antagonists | ROCHE PALO ALTO LLC | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224964-A1 | Heterocyclic derivatives as CRF antagonists | CRHR1, CRHR2, CNR1 | PDE3B 872/4885PDE3A 730/4885CRBN 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.